S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
Ben Stein FREE Report: How Americans Are RUINING Retirement (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023

Best Stocks Under $50.00 Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $50.00 (50 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.


Bird Construction stock logo

#1 - Bird Construction

OTCMKTS:BIRDF
Stock Price: $6.55
PE Ratio: 9.58
Average Trading Volume: 1,746 shares
P/E Ratio: 9.6
Dividend Yield: 6.68%
Consensus Rating: Strong Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.80 (64.9% Upside)
Bird Construction Inc. provides construction services in Canada. The company primarily focuses on projects in the industrial, commercial, and institutional, and civil infrastructure markets. It constructs large, complex industrial buildings, including manufacturing, processing, distribution, and warehouse facilities; and provides electrical and instrumentation, high voltage testing and commissioning services, as well as power line construction, structural, mechanical, and piping, including off-site metal and modular fabrication. The company also engages in the civil construction operations, such as site preparation and earthworks, underground piping, utilities and foundation, and other concrete services, as well as mine support and greenfield and brownfield hydroelectric construction service; and civil infrastructure operations comprising road, bridge, rail, and underground utilities installation. In addition, it constructs and retrofits institutional facilities, include healthcare facilities, post-secondary education facilities, K-12 schools, recreation facilities, public transportation facilities, prisons, courthouses, government buildings, and long term care and senior housing facilities; and constructs and residential sector, include new construction and retrofit of data centers, office buildings, retail facilities, film studio infrastructure, hotels, and mixed-use mid- to high-rise residential buildings. Further, it offers electrical and related system services, which include electrical and mechanical infrastructure design and installation, data communications, security, and lifecycle services. It serves clients in the oil and gas, liquefied natural gas, mining, renewables, water and wastewater, nuclear, infrastructure, and residential sectors. Bird Construction Inc. was founded in 1920 and is based in Mississauga, Canada.
JD Sports Fashion stock logo

#2 - JD Sports Fashion

OTCMKTS:JDSPY
Stock Price: $1.95
Average Trading Volume: 3,229 shares
Consensus Rating: Strong Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $205.83 (10,455.6% Upside)
JD Sports Fashion plc engages in the retail of branded sports fashion and outdoor clothing, footwear, accessories, and equipment for kids, women, and men. It operates through Sports Fashion and Outdoor segments. The company also retails leisure goods, sports goods, fishing gear, camping goods, boats, and bicycles, as well as distributes sports apparel and accessories, footwear, and apparel. It offers its products under the JD, Size?, Footpatrol, Finish Line, Shoe Palace, DTLR, Livestock, Sprinter, Sport Zone, Sizeer, JD Gyms, Tessuti, Scotts, Go Outdoors, Blacks, Millets, Tiso, Ultimate Outdoors, Fishing Republic, and Naylors brands. The company also operates online business. In addition, it licenses fashion brands and operates fitness centers; operates as online own label women's fashion retailer; and manufactures and distributes professional fitness equipment. The company has operations in the United Kingdom, Andorra, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Latvia, Lithuania, Malaysia, the Netherlands, New Zealand, Poland, Portugal, Republic of Ireland, Romania, Serbia, Singapore, Slovakia, South Korea, Spain and the Canary Islands, Sweden, Thailand, and the United Arab Emirates. The company was founded in 1981 and is headquartered in Bury, the United Kingdom. JD Sports Fashion plc is a subsidiary of Pentland Group Limited.
Northland Power stock logo

#3 - Northland Power

OTCMKTS:NPIFF
Stock Price: $18.06 (+$0.05)
PE Ratio: -57.13
Average Trading Volume: 8,778 shares
Dividend Yield: 7.24%
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $50.75 (181.0% Upside)
Northland Power Inc., an independent power producer, develops, builds, owns, and operates clean and green power projects in North America, Europe, Latin America, and Asia. The company produces electricity from renewable resources, such as wind, solar, or hydropower, as well as clean-burning natural gas and biomass for sale under power purchase agreements and other revenue arrangements. It owned or had an economic interest in 3.2 gigawatts of operating generating capacity. The company was founded in 1987 and is headquartered in Toronto, Canada.
Mirum Pharmaceuticals stock logo

#4 - Mirum Pharmaceuticals

NASDAQ:MIRM
Stock Price: $25.79 (+$0.34)
PE Ratio: -5.43
Market Cap: $980.85 million
Average Trading Volume: 491,322 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $49.00 (90.0% Upside)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Dyne Therapeutics stock logo

#5 - Dyne Therapeutics

NYSE:DYN
Stock Price: $10.58 (+$0.65)
PE Ratio: -3.11
Market Cap: $645.59 million
Average Trading Volume: 421,664 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $25.83 (144.2% Upside)
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
InflaRx stock logo

#6 - InflaRx

NASDAQ:IFRX
Stock Price: $3.65 (+$0.08)
PE Ratio: -5.89
Market Cap: $163.16 million
Average Trading Volume: 1.13 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.00 (283.6% Upside)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
89bio stock logo

#7 - 89bio

NASDAQ:ETNB
Stock Price: $15.89 (+$0.30)
PE Ratio: -5.63
Market Cap: $1.16 billion
Average Trading Volume: 1.65 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $38.13 (139.9% Upside)
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Avidity Biosciences stock logo

#8 - Avidity Biosciences

NASDAQ:RNA
Stock Price: $9.35 (+$0.42)
PE Ratio: -2.78
Market Cap: $662.17 million
Average Trading Volume: 1.09 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $38.17 (308.2% Upside)
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Energy Transfer stock logo

#9 - Energy Transfer

NYSE:ET
Stock Price: $12.99 (+$0.10)
PE Ratio: 10.82
Market Cap: $40.81 billion
Average Trading Volume: 11.41 million shares
P/E Ratio: 10.8
Dividend Yield: 9.51%
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.57 (27.6% Upside)
Energy Transfer LP provides energy-related services. The company owns and operates approximately 11,600 miles of natural gas transportation pipeline, and three natural gas storage facilities in Texas and two natural gas storage facilities located in the state of Texas and Oklahoma; and 19,945 miles of interstate natural gas pipeline. It also sells natural gas to electric utilities, independent power plants, local distribution and other marketing companies, and industrial end-users. The company owns and operates natural gas gathering and natural gas liquid (NGL) pipeline, processing plant, and treating and conditioning facilities in Texas, New Mexico, West Virginia, Pennsylvania, Ohio, Oklahoma, Arkansas, Kansas, and Louisiana; natural gas gathering, oil pipeline, and oil stabilization facilities in South Texas; and a natural gas gathering system in Ohio, as well as transport and supplies water to natural gas producer in Pennsylvania. It owns approximately 5,650 miles of NGL pipeline; NGL fractionation facilities; NGL storage facilities with working storage capacity of approximately 58 million barrels (MMBbls); and other NGL storage assets and terminal with an aggregate storage capacity of approximately 25 MMBbls. The company provides crude oil transportation, terminalling, acquisition, and marketing activities; and sells and distributes gasoline, middle distillate, and motor fuels and other petroleum product. It offers natural gas compression service; carbon dioxide and hydrogen sulfide removal service; and manages coal and natural resources properties, as well as sells standing timber, leases coal-related infrastructure facilities, collects oil and gas royalty, and generate electrical power. The company was formerly known as Energy Transfer Equity, L.P. and changed its name to Energy Transfer LP in October 2018. Energy Transfer LP was founded in 1996 and is headquartered in Dallas, Texas.
Northern Oil and Gas stock logo

#10 - Northern Oil and Gas

NYSE:NOG
Stock Price: $42.40 (+$0.56)
PE Ratio: 2.97
Market Cap: $3.94 billion
Average Trading Volume: 1.61 million shares
P/E Ratio: 3.0
Dividend Yield: 3.54%
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $46.67 (10.1% Upside)
Northern Oil and Gas, Inc., an independent energy company, engages in the acquisition, exploration, exploitation, development, and production of crude oil and natural gas properties in the United States. It primarily holds interests in the Williston Basin, the Appalachian Basin, and the Permian Basin in the United States. The company is based in Minnetonka, Minnesota.
CymaBay Therapeutics stock logo

#11 - CymaBay Therapeutics

NASDAQ:CBAY
Stock Price: $12.63 (+$0.23)
PE Ratio: -10.70
Market Cap: $1.23 billion
Average Trading Volume: 1.73 million shares
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $16.00 (26.7% Upside)
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Atlas Energy Solutions stock logo

#12 - Atlas Energy Solutions

NYSE:AESI
Stock Price: $20.31 (-$0.54)
Market Cap: $2.09 billion
Average Trading Volume: 405,121 shares
Dividend Yield: 0.72%
Consensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $24.70 (21.6% Upside)
Atlas Energy Solutions Inc. provides proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico. The company was founded in 2017 and is based in Austin, Texas.
Xenon Pharmaceuticals stock logo

#13 - Xenon Pharmaceuticals

NASDAQ:XENE
Stock Price: $35.45 (+$0.10)
PE Ratio: -15.28
Market Cap: $2.25 billion
Average Trading Volume: 373,879 shares
Consensus Rating: Buy (12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $51.64 (45.7% Upside)
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xencor stock logo

#14 - Xencor

NASDAQ:XNCR
Stock Price: $23.08 (-$0.78)
PE Ratio: -10.78
Market Cap: $1.40 billion
Average Trading Volume: 338,851 shares
Consensus Rating: Buy (12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $44.20 (91.5% Upside)
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Delta Air Lines stock logo

#15 - Delta Air Lines

NYSE:DAL
Stock Price: $45.03 (-$0.76)
PE Ratio: 9.70
Market Cap: $28.77 billion
Average Trading Volume: 10.73 million shares
P/E Ratio: 9.7
Dividend Yield: 0.90%
Consensus Rating: Buy (13 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $56.88 (26.3% Upside)
Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo in the United States and internationally. The company operates through two segments, Airline and Refinery. Its domestic network centered on core hubs in Atlanta, Minneapolis-St. Paul, Detroit, and Salt Lake City, as well as coastal hub positions in Boston, Los Angeles, New York-LaGuardia, New York-JFK, and Seattle; and international network centered on hubs and market presence in Amsterdam, Mexico City, London-Heathrow, Paris-Charles de Gaulle, and Seoul-Incheon. The company sells its tickets through various distribution channels, including delta.com and the Fly Delta app, reservations, online travel agencies, traditional brick and mortar, and other agencies. It also provides aircraft maintenance and engineering support, repair, and overhaul services; and vacation packages to third-party consumers, as well as aircraft charters, and management and programs. The company operates through a fleet of approximately 1,250 aircrafts. Delta Air Lines, Inc. was founded in 1924 and is based in Atlanta, Georgia.
Halliburton stock logo

#16 - Halliburton

NYSE:HAL
Stock Price: $40.46 (+$0.68)
PE Ratio: 14.88
Market Cap: $36.36 billion
Average Trading Volume: 9.41 million shares
P/E Ratio: 14.9
Dividend Yield: 1.62%
Consensus Rating: Buy (15 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $47.47 (17.3% Upside)
Halliburton Company provides products and services to the energy industry worldwide. It operates in two segments, Completion and Production, and Drilling and Evaluation. The Completion and Production segment offers production enhancement services that include stimulation and sand control services; cementing services, such as well bonding and casing, and casing equipment; completion tools that offer downhole solutions and services, including well completion products and services, intelligent well completions, and service tools, as well as liner hanger, sand control, and multilateral systems; production solutions comprising coiled tubing, hydraulic workover units, downhole tools, and pumping and nitrogen services; and pipeline and process services, such as pre-commissioning, commissioning, maintenance, and decommissioning. This segment also provides electrical submersible pumps, as well as artificial lift services. The Drilling and Evaluation segment offers drilling fluid systems, performance additives, completion fluids, solids control, specialized testing equipment, and waste management services; oilfield completion, production, and downstream water and process treatment chemicals and services; drilling systems and services; wireline and perforating services consists of open-hole logging, and cased-hole and slickline; and drill bits and services comprising roller cone rock bits, fixed cutter bits, hole enlargement, and related downhole tools and services, as well as coring equipment and services. This segment also provides cloud based digital services and artificial intelligence solutions on an open architecture for subsurface insights, integrated well construction, and reservoir and production management; testing and subsea services, such as acquisition and analysis of reservoir information and optimization solutions; and project management and integrated asset management services. Halliburton Company was founded in 1919 and is based in Houston, Texas.
Everi stock logo

#17 - Everi

NYSE:EVRI
Stock Price: $12.94 (-$1.67)
PE Ratio: 10.69
Market Cap: $1.15 billion
Average Trading Volume: 770,686 shares
P/E Ratio: 10.7
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $25.20 (94.7% Upside)
Everi Holdings Inc. develops and supplies entertaining game content, gaming machines, and gaming systems and services for land-based and iGaming operators in the United States, Canada, Australia, the United Kingdom, Europe, the Caribbean, Central America, and Asia. It operates in two segments, Games and Financial Technology Solutions. The company offers classic mechanical reel games and video reel games, as well as TournEvent of Champions, a national slot tournament; and sells gaming equipment and player terminals, licenses, game content, and ancillary equipment, such as signage and lighting packages. It also provides financial access services, such as funds dispensed and transmitted, credit card and POS debit card financial access transactions; check warranty; CashClub, a software payments platform that provides gaming operators with a personal computer workstation software user interface and point-of-sale terminal; CashClub Wallet, a digital payments platform for gaming operators; fully integrated kiosks that provide multiple functions to gaming operators on their casino floors; loyalty kiosk and related equipment; and other integrated kiosk solutions. In addition, the company offers non-funds dispensing terminals that perform authorizations for credit card financial access and POS debit card financial access transactions; and database services. Further, it provides Everi Compliance, a anti-money laundering management tool; Central Credit, a gaming patron credit bureau service; JackpotXpress, a jackpot payout and tax form management platform; and Loyalty platform, a software platform to adopt and deliver new promotional strategies, as well as support and maintenance services. It offers products for the casino, sports, entertainment, and hospitality industries. The company was formerly known as Global Cash Access Holdings, Inc. and changed its name to Everi Holdings Inc. in August 2015. Everi Holdings Inc. was founded in 1998 and is based in Las Vegas, Nevada.
Delivery Hero stock logo

#18 - Delivery Hero

OTCMKTS:DLVHF
Stock Price: $42.50 (-$2.50)
Average Trading Volume: 1,909 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $69.26 (63.0% Upside)
Delivery Hero SE offers online food ordering and delivery services. It operates approximately in 50 countries in Europe, the Middle East, North Africa, Asia, and the Americas. The company was founded in 2011 and is headquartered in Berlin, Germany.
Inspired Entertainment stock logo

#19 - Inspired Entertainment

NASDAQ:INSE
Stock Price: $12.55 (-$0.81)
PE Ratio: 17.68
Market Cap: $329.69 million
Average Trading Volume: 135,471 shares
P/E Ratio: 17.7
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $21.75 (73.3% Upside)
Inspired Entertainment, Inc., a gaming technology company, engages in the supply of content, platform, and other products and services to regulated lottery, betting, and gaming operators worldwide. It operates in four segments: Gaming, Virtual Sports, Interactive, and Leisure. The Gaming segment supplies gaming terminals and software to betting offices, casinos, gaming halls, and high street adult gaming centers; a portfolio of games through its digital terminals under the Centurion and Super Hot Fruits names; and traditional casino games, such as roulette, blackjack, and number games. The Virtual Sports segment designs, develops, markets, and distributes ultra-high-definition sports games, including greyhounds, tennis, motor racing, cycling, cricket, speedway, golf, and dart, and other horse racing games under the V-Play Soccer, V-Play Women's Soccer, V-Play Football, V-Play Basketball, V-Play Baseball, and V-Play NFLA names. The Interactive segment provides a range of premium random number generated casino content from feature-rich bonus games to European-style casino free spins and table games. The Leisure segment supplies gaming terminals and amusement machines in pubs, bingo halls, and adult gaming centers, as well as family entertainment centers, bowling centers, and other entertainment venues. Inspired Entertainment, Inc. is headquartered in New York, New York.
Magnolia Oil & Gas stock logo

#20 - Magnolia Oil & Gas

NYSE:MGY
Stock Price: $23.21 (+$0.22)
PE Ratio: 6.69
Market Cap: $4.92 billion
Average Trading Volume: 2.04 million shares
P/E Ratio: 6.7
Dividend Yield: 1.99%
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $27.50 (18.5% Upside)
Magnolia Oil & Gas Corporation engages in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquids reserves in the United States. Its properties are located primarily in Karnes County and the Giddings area in South Texas principally comprising the Eagle Ford Shale and the Austin Chalk formation. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Sixth Street Specialty Lending stock logo

#21 - Sixth Street Specialty Lending

NYSE:TSLX
Stock Price: $20.40 (-$0.10)
PE Ratio: 8.95
Market Cap: $1.78 billion
Average Trading Volume: 431,423 shares
P/E Ratio: 8.9
Dividend Yield: 8.95%
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $21.00 (2.9% Upside)
Sixth Street Specialty Lending, Inc. (NYSE: TSLX) is a business development company. The fund provides senior secured loans (first-lien, second-lien, and unitranche), unsecured loans, mezzanine debt, and investments in corporate bonds and equity securities and structured products, non-control structured equity, and common equity with a focus on co-investments for organic growth, acquisitions, market or product expansion, restructuring initiatives, recapitalizations, and refinancing. The fund invests in business services, software & technology, healthcare, energy, consumer & retail, manufacturing, industrials, royalty related businesses, education, and specialty finance. It seeks to finance and lending to middle market companies principally located in the United States. The fund invests in companies with enterprise value between $50 million and $1 billion or more and EBITDA between $10 million and $250 million. The transaction size is between $15 million and $350 million. The fund invests across the spectrum of the capital structure and can arrange syndicated transactions of up to $500 million and hold sizeable positions within its credits.
Ardelyx stock logo

#22 - Ardelyx

NASDAQ:ARDX
Stock Price: $3.96 (+$0.08)
PE Ratio: -13.66
Market Cap: $862.73 million
Average Trading Volume: 6.14 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.70 (69.2% Upside)
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
The Liberty SiriusXM Group stock logo

#23 - The Liberty SiriusXM Group

NASDAQ:LSXMA
Stock Price: $23.12 (+$0.42)
PE Ratio: 7.20
Market Cap: $2.27 billion
Average Trading Volume: 1.81 million shares
P/E Ratio: 7.2
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $49.67 (114.8% Upside)
The Liberty SiriusXM Group, through its subsidiaries, engages in the entertainment business in the United States and Canada. It features music, sports, entertainment, comedy, talk, news, traffic, weather channels, podcast, and infotainment services through proprietary satellite radio systems, as well as streamed through applications for mobile and home devices, and other consumer electronic equipment. It also offers connected vehicle services; a suite of data services that include graphical weather, fuel prices, sports schedules and scores, and movie listings; and traffic information services, which provide information as to road closings, traffic flow and incident data to consumers with compatible in-vehicle navigation systems, and real-time weather services in vehicles, boats, and planes. In addition, the company operates a music, comedy, and podcast streaming platform. Further, it offers ad-supported radio services; Pandora Plus, a radio subscription service; and Pandora Premium, an on-demand subscription service. Additionally, the company distributes satellite radios through automakers and retailers, as well as through its website. As of December 31, 2021, it served approximately 34.0 million subscribers through Sirius XM and approximately 6.4 million subscribers through Pandora. The Liberty SiriusXM Group is based in Englewood, Colorado. The Liberty SiriusXM Group operates as a subsidiary of Liberty Media Corporation.
Alarm.com stock logo

#24 - Alarm.com

NASDAQ:ALRM
Stock Price: $49.21 (-$0.55)
PE Ratio: 41.70
Market Cap: $2.45 billion
Average Trading Volume: 216,901 shares
P/E Ratio: 41.7
Consensus Rating: Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $64.25 (30.6% Upside)
Alarm.com Holdings, Inc. provides various Internet of Things (IoT) and solutions for residential, multi-family, small business, and enterprise commercial markets in North America and internationally. The company operates in two segments, Alarm.com and Other. It offers solutions to control and monitor security systems, as well as to IoT devices, including door locks, garage doors, thermostats, and video cameras; and video monitoring and analytics solutions, such as escalated events, video doorbells, intelligent integration, live streaming, secure cloud storage, and video alerts. The company also provides scenes, video analytics triggers, thermostat schedules, responsive savings, precision comfort, energy usage monitoring, places feature, demand response programs, whole home water safety, and solar monitoring solutions, as well as heating, ventilation, and air conditioning monitoring services. In addition, it offers commercial grade video, commercial video analytics, access control, enterprise dashboard and multi-site management, energy savings, protection for valuables and inventory, temperature monitoring, and daily safeguard solutions. Further, the company provides a permission-based online portal that provides account management, sales, marketing, training, and support tools; a unified interface that displays key operational and customer experience indicators, including technician performance, system reliability and customer engagement metrics; installation and support services; MobileTech Application and Remote Toolkit; video health reports; smart gateway; AI-powered enhancements to professional monitoring and false alarm reduction; Web services and business intelligence; sales, marketing, and training services; and home builder programs. Additionally, it offers electric utility grid and water management, indoor gunshot detection, and health and wellness and data-rich emergency response solutions. The company was founded in 2000 and is based in Tysons, Virginia.
Genco Shipping & Trading stock logo

#25 - Genco Shipping & Trading

NYSE:GNK
Stock Price: $14.36 (+$0.41)
PE Ratio: 7.36
Market Cap: $610.23 million
Average Trading Volume: 878,932 shares
P/E Ratio: 7.4
Dividend Yield: 4.28%
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $23.40 (63.0% Upside)
Genco Shipping & Trading Limited, together with its subsidiaries, engages in the ocean transportation of dry bulk cargoes worldwide. The company owns and operates dry bulk carrier vessels to transports iron ore, grains, coal, steel products, and other dry-bulk cargoes. It charters its vessels primarily to trading houses, including commodities traders; producers; and government-owned entities. The company was incorporated in 2004 and is headquartered in New York, New York.

More Stock Ideas from MarketBeat

My Account -